The IGF2BP3 Knockout KYSE-30 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population derived from the KYSE-30 human esophageal squamous cell carcinoma (ESCC) line, engineered for disruption of the IGF2BP3 gene. This pooled format yields a heterogeneous loss-of-function model in which target gene disruption is achieved across a mixed cellular population, enabling robust genotype-phenotype correlation studies without clonal isolation. As a research-grade reagent, these polyclonal knockout cells are optimized for applications requiring unbiased assessment of IGF2BP3 function in a malignancy-relevant background and support downstream analyses including transcriptomic, proteomic, and phenotypic assays.
KYSE-30 cells originate from a well-differentiated esophageal squamous cell carcinoma resected from a 64-year-old male patient, representing a widely cited cellular model for ESCC biology. This adherent cell line retains characteristic features of primary tumors, such as morphological hallmarks and signaling dependency, and is frequently employed to interrogate oncogenic mechanisms, therapeutic vulnerabilities, and metastasis in esophageal cancer. Its robust growth and experimental tractability make it a valuable host for CRISPR-based modification, facilitating dissection of gene-specific contributions within the genomic and epigenomic context of ESCC.
IGF2BP3 encodes an oncofetal RNA-binding protein that post-transcriptionally regulates a network of target mRNAs by stabilizing transcripts and enhancing their translation. It is positively controlled by upstream factors including MYC, LIN28B, and ??-catenin/TCF, and suppressed by let?7 miRNA. Once expressed, IGF2BP3 directly interacts with mRNAs such as MYC, CDK6, HMGA2, LIN28B, Gli1, and IGF1R, shielding them from degradation and promoting synthesis of proteins that drive proliferation, migration, and invasion. Mechanistically, it interfaces with the translation machinery via interactions with eIF4E, the RNA-binding protein ELAVL1 (HuR), LIN28B, DDX6, and RNA helicases, thereby converging on key cancer pathways including PI3K/AKT, MAPK/ERK, and WNT/???catenin. Its action ultimately contributes to sustained expression of MYC and CDK6, linking extracellular signals to cell-cycle progression and epithelial-to-mesenchymal transition.
In the KYSE-30 background, IGF2BP3 contributes to the malignant phenotype by stabilizing pro-tumorigenic mRNAs, and its genetic disruption is expected to attenuate traits such as anchorage-independent growth, motility, and invasive capacity. This knockout model thus serves as a critical tool for dissecting the post-transcriptional circuitry that underlies ESCC aggressiveness. Researchers can utilize the cells to directly compare wild-type and knockout phenotypes, assess the reliance on IGF2BP3-mediated mRNA stabilization for survival and metastatic potential, and identify compensatory pathways that emerge upon loss of this hub. The system is particularly well-suited for mechanistic studies linking RNA stability regulation to tumor-cell behavior in esophageal cancer.
Research applications span cancer and RNA biology, drug target validation, epithelial-to-mesenchymal transition, and metastasis modeling. Recommended assays include western blotting and RT?qPCR to confirm IGF2BP3 ablation and quantify changes in target mRNAs, transcriptome-wide RNA?seq to globally assess post-transcriptional alterations, MTT or BrdU proliferation assays, Transwell migration and invasion tests, and in vivo xenograft tumorigenicity studies. Additionally, RNA immunoprecipitation (RIP) and immunofluorescence can further characterize remaining RNA?Cprotein interactions and subcellular localization. For additional details on lot-specific validation data and technical support, please contact Ascent Research.
